Fennec Pharmaceuticals Inc. (FENC)
FENC moved a median of +0.09% 30 minutes after news, and +0.11% by the close. How FENC actually reacts to news — the realized, point-in-time move the market made, measured across 364 labeled events over the last three years with zero look-ahead.
FENC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 353 |
| 30-min | +0.09% | 51% | 363 |
| 60-min | 0.00% | 50% | 363 |
| to close | +0.11% | 51% | 364 |
| Middle 50% of FENC reactions | -0.98% to +1.20% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 364 |
Half of all Fennec Pharmaceuticals Inc. news events land between -0.98% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when FENC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FENC's baseline. Nothing else.
Recent FENC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 | Press release | GlobeNewswire | +0.00% | +0.37% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -1.48% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.57% | -3.06% | |
| Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.49% | +5.10% | |
| Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 | Press release | GlobeNewswire | +0.00% | +2.94% | |
| Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | +0.66% | +4.38% | |
| Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -0.77% | +1.21% | |
| Form S-8 FENNEC PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +2.25% | +1.12% | |
| Fennec Announces Results of Annual Meeting | Press release | GlobeNewswire | -0.92% | +1.49% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | +1.49% | |
| Form 8-K FENNEC PHARMACEUTICALS For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | -0.80% | |
| Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -0.39% | -3.40% | |
| Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +2.52% | |
| Form 8-K FENNEC PHARMACEUTICALS For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.52% | |
| Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +10.56% | +28.33% | |
| Form 10-Q FENNEC PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.90% | +5.63% | |
| Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | GlobeNewswire | -0.84% | -3.36% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -2.30% | -6.01% | |
| Form DEF 14A FENNEC PHARMACEUTICALS For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -2.30% | -6.01% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -0.45% | |
| Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.00% | +1.21% | |
| Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center | Press release | GlobeNewswire | -0.16% | +1.77% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -1.82% | -1.52% | |
| Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.51% | +4.41% | |
| Form 10-K FENNEC PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.23% | -1.03% | |
| Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +9.50% | -2.27% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +2.87% | +4.05% | |
| Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 | Press release | GlobeNewswire | +0.71% | -3.11% | |
| Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation | Press release | GlobeNewswire | +1.47% | +0.52% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +1.34% | -0.77% | |
| Form S-8 FENNEC PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +2.63% | -1.28% | |
| Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute | Press release | GlobeNewswire | +0.00% | +1.49% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -3.29% | |
| Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers | Press release | GlobeNewswire | +0.57% | +0.00% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.98% | |
| Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) | Press release | GlobeNewswire | -1.49% | -4.35% | |
| Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | Press release | GlobeNewswire | -0.66% | +0.53% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | — | -2.87% | |
| Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss | Press release | GlobeNewswire | -1.80% | -2.06% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.40% | |
| Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.00% | -0.13% | |
| Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption | Press release | GlobeNewswire | +1.13% | -7.57% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -7.57% | |
| Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -7.57% | |
| Form S-8 FENNEC PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +1.13% | -7.57% | |
| Fennec Pharmaceuticals Announces Closing of Offering of Common Shares | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K FENNEC PHARMACEUTICALS For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +5.33% | +9.79% | |
| Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares | Press release | GlobeNewswire | -8.57% | -10.17% | |
| Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada | Press release | GlobeNewswire | -8.57% | -10.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FENC section they belong to.
Where else FENC is measured.
FENC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SOPHIRIS BIO INC (SPHS) | 366 | -0.23% | 37% |
| EISAI CO S/ADR (ESALY) | 365 | 0.00% | 33% |
| RadNet, Inc. (RDNT) | 364 | +0.09% | 53% |
| Aerpio Pharmaceuticals, Inc (ARPO) | 363 | 0.00% | 32% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Fennec Pharmaceuticals Inc.'s median reaction calculated?
Every labeled FENC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 364 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of FENC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FENC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.